Promising drug is victim of bad business.
Dove
Alan
A
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D000077146:Irinotecan; D010330:Patents as Topic; D011993:Recombinant Fusion Proteins / Q000191:economics / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; D000077146:Irinotecan; D066246:ErbB Receptors; D000068818:Cetuximab; D002166:Camptothecin